The announcement follows just days after the US Centres for Disease Control confirmed its first death from Avian Influenza.
IO Biotech has finished enrolling subjects in a Phase II trial of IO102-IO103 in conjunction with MSD's KEYTRUDA (pembrolizumab).
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback